# Phase 1/2 endometrial cancer trials recruiting: 51 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 51 trials in phase 1/2 for endometrial cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 endometrial cancer trials: 51 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/endometrial-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 51
- Recruiting or not yet: 51
- Read on: November 19, 2026

## Trials

The 25 newest of 51, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 2, 2026 | NCT07909031 | CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors | Crescent Biopharma, Inc. | Phase 1/2 | Recruiting | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC)... | 219 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909031) |
| September 10, 2026 | NCT07811297 | A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers | Advenchen Pharmaceuticals, LLC. | Phase 1/2 | Not yet recruiting | Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811297) |
| September 10, 2026 | NCT07811232 | A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers | Advenchen Pharmaceuticals, LLC. | Phase 1/2 | Not yet recruiting | Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811232) |
| August 7, 2026 | NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | LG Chem | Phase 1/2 | Not yet recruiting | Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer, Breast... | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07752875) |
| August 4, 2026 | NCT07743541 | Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy | Gilead Sciences | Phase 1/2 | Not yet recruiting | Uterine Endometrial Cancer | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743541) |
| May 29, 2026 | NCT07612891 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With... | Shenzhen Ionova Life Sciences Co., Ltd. | Phase 1/2 | Recruiting | Breast Cancer (Locally Advanced or Metastatic), Advanced Solid Cancers, Metastatic (Stage IV) Breast Cancer, Ovarian... | 201 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07612891) |
| May 28, 2026 | NCT07610798 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced... | Shenzhen Ionova Life Sciences Co., Ltd. | Phase 1/2 | Recruiting | Advance Solid Tumors, Colon and Rectal Cancer, Non - Small Cell Lung Cancer NSCLC, Pancreatic Adenocarcinoma Advanced... | 178 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07610798) |
| March 6, 2026 | NCT07453394 | QLS5132 Combination Therapy in Advanced Solid Tumors | Qilu Pharmaceutical Co., Ltd. | Phase 1/2 | Not yet recruiting | Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC), Endometrial Cancer, Advanced Solid Tumors, Ovarian Cancer | 626 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07453394) |
| January 28, 2026 | NCT07371663 | An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors | Beijing Tide Pharmaceutical Co., Ltd | Phase 1/2 | Recruiting | Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer), Gastric (Stomach) Cancer, Endometrial Cancer, Malignant... | 266 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07371663) |
| January 14, 2026 | NCT07341737 | SL-28 for Advanced Solid Tumours | Second Life Therapeutics | Phase 1/2 | Recruiting | Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma, Lung Cancer (NSCLC), Lung... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07341737) |
| December 3, 2025 | NCT07262619 | EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With... | Eikon Therapeutics | Phase 1/2 | Recruiting | Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer... | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07262619) |
| October 9, 2025 | NCT07213609 | A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in... | GlaxoSmithKline | Phase 1/2 | Recruiting | Neoplasms, Colorectal, Neoplasms | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07213609) |
| September 24, 2025 | NCT07189871 | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors | Radiopharm Theranostics, Ltd | Phase 1/2 | Recruiting | Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer... | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07189871) |
| September 22, 2025 | NCT07186842 | A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known... | BioNTech SE | Phase 1/2 | Recruiting | Advanced Solid Cancers | 245 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07186842) |
| August 7, 2025 | NCT07109726 | A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations | Terremoto Biosciences Inc. | Phase 1/2 | Recruiting | Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma... | 248 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07109726) |
| July 17, 2025 | NCT07070518 | Study of GV20-0251 in Participants With Solid Tumor Malignancies | GV20 Therapeutics | Phase 1/2 | Recruiting | Solid Tumor Cancer, Adult Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, pMMR/MSS... | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07070518) |
| June 13, 2025 | NCT07020221 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | Verastem, Inc. | Phase 1/2 | Recruiting | Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS | 616 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07020221) |
| May 29, 2025 | NCT06993844 | Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors | Ensem Therapeutics | Phase 1/2 | Recruiting | Advanced Solid Tumors, Advanced Breast Cancer | 233 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06993844) |
| April 24, 2025 | NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | Tanabe Pharma America, Inc. | Phase 1/2 | Recruiting | Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06943521) |
| January 3, 2025 | NCT06758557 | A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor | Huabo Biopharm Co., Ltd. | Phase 1/2 | Recruiting | Advanced NSCLC, Advanced Endometrial Cancer | 282 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06758557) |
| December 27, 2024 | NCT06751329 | A Study of DM002 in Patients With Advanced Solid Tumors | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | Phase 1/2 | Recruiting | Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Colorectal Neoplasms, Solid Carcinoma, Pancreatic Cancer | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06751329) |
| October 1, 2024 | NCT06620029 | BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer | BioMimetix JV, LLC | Phase 1/2 | Not yet recruiting | Ovarian Neoplasms, Endometrial Cancer, Endometrial Neoplasm | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06620029) |
| May 2, 2024 | NCT06395519 | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies | 858 Therapeutics, Inc. | Phase 1/2 | Recruiting | Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Epithelial Ovarian Cancer, BRCA2... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06395519) |
| March 26, 2024 | NCT06330064 | A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors... | Daiichi Sankyo | Phase 1/2 | Recruiting | Recurrent or Metastatic Solid Tumors | 680 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06330064) |
| February 12, 2024 | NCT06253494 | Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in... | National Cancer Institute (NCI) | Phase 1/2 | Recruiting | Endometrial Cancer, Cancer of Endometrium, Carcinoma of Endometrium, Endometrial Carcinoma | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06253494) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Shenzhen Ionova Life Sciences Co., Ltd. | 2 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 2 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 2 |
| Advenchen Pharmaceuticals, LLC. | 2 |
| GV20 Therapeutics | 2 |
| Volastra Therapeutics, Inc. | 1 |
| Parabilis Medicines, Inc. | 1 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 1 |
| PMV Pharmaceuticals, Inc | 1 |
| DualityBio Inc. | 1 |
| Eikon Therapeutics | 1 |
| National Cancer Institute (NCI) | 1 |
| Huabo Biopharm Co., Ltd. | 1 |
| BioMimetix JV, LLC | 1 |
| 858 Therapeutics, Inc. | 1 |
| [BioNTech SE](https://specstream.ai/data/clinical-trials/company/biontech-se) | 1 |
| ModeX Therapeutics, An OPKO Health Company | 1 |
| Avenzo Therapeutics, Inc. | 1 |
| LigaChem Biosciences, Inc. | 1 |
| Artios Pharma Ltd | 1 |
| Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | 1 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 1 |
| Marengo Therapeutics, Inc. | 1 |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 1 |
| [Tanabe Pharma America, Inc.](https://specstream.ai/data/clinical-trials/company/tanabe-pharma-america-inc) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 41 |
| Spain | 17 |
| Australia | 13 |
| France | 13 |
| China | 11 |
| Italy | 9 |
| Japan | 8 |
| South Korea | 8 |
| United Kingdom | 8 |
| Netherlands | 7 |
| Germany | 7 |
| Belgium | 6 |
| Canada | 5 |
| Taiwan | 4 |
| Poland | 4 |
| Puerto Rico | 3 |
| Portugal | 3 |
| Ireland | 3 |
| Singapore | 2 |
| Brazil | 2 |
| Israel | 2 |
| Turkey (Türkiye) | 2 |
| Denmark | 1 |
| Sweden | 1 |
| Hungary | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Clinical laboratories in the United States](https://specstream.ai/data/businesses/clinical-laboratories/united-states)
- [Hardware and fastener manufacturers in the United States](https://specstream.ai/data/businesses/hardware-and-fastener-manufacturers/united-states)
- [Packing supply stores in the United States](https://specstream.ai/data/businesses/packing-supply-stores/united-states)
- [Textile mills in the United States](https://specstream.ai/data/businesses/textile-mills/united-states)
- [Beer bars in the United States](https://specstream.ai/data/businesses/beer-bars/united-states)
- [Eye care clinics in the United States](https://specstream.ai/data/businesses/eye-care-clinics/united-states)
